Highlights of international frontier hot spots and new progress on renal transplantation in 2020

Shao kun; Wang Xianghui

doi:10.3969/j.issn.1674-7445.2021.02.005

Volume 12 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2021 > 12(2): 155-168

Shao kun, Wang Xianghui. Highlights of international frontier hot spots and new progress on renal transplantation in 2020[J]. ORGAN TRANSPLANTATION, 2021, 12(2): 155-168. doi: 10.3969/j.issn.1674-7445.2021.02.005

Citation:

PDF( 953 KB)

Highlights of international frontier hot spots and new progress on renal transplantation in 2020

doi: 10.3969/j.issn.1674-7445.2021.02.005

Shao kun,
Wang Xianghui^,

Kidney Transplant Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

More Information

Corresponding author: Wang Xianghui, E-mail: wxh@medmail.com.cn
Received Date: 2021-01-25
Available Online: 2021-03-19
Publish Date: 2021-03-15

Abstract

Abstract

A large quantity of studies related to renal transplantation were reviewed to extract and summarize the international frontier hot spots and difficulties, new transplantation technologies, new methods, new visions and new progress on renal transplantation in 2020.The main contents included rejection, optimization application and regulation of immunosuppression, transplant infection, malignancy after transplantation, non-invasive detection and biomarkers, donor organ preservation, repair and utilization, recurrence of renal disease after renal transplantation, multi-factors affecting long-term survival of transplant kidney, computer and artificial intelligence, etc.Strengthening the reading and thinking of literatures in the field of renal transplantation and broadening horizons in higher starting piont, combined with clinical practice of renal transplantation in China, help to promote the long-term efficacy of renal transplantation.
- Renal transplantation,
- Donor specific antibody,
- Rejection,
- Transplantation immunity,
- Infection,
- Non-invasive detection,
- Machine perfusion,
- Artificial intelligence

FullText(HTML)

References(51)

References

[1]	SELLARÉS J, DE FREITAS DG, MENGEL M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence[J]. Am J Transplant, 2012, 12(2): 388-399. DOI: 10.1111/j.1600-6143.2011.03840.x.
[2]	TAMBUR AR, CAMPBELL P, CHONG AS, et al. Sensitization in transplantation: assessment of risk (STAR)2019 working group meeting report[J]. Am J Transplant, 2020, 20(10): 2652-2668. DOI: 10.1111/ajt.15937.
[3]	NICKERSON PW. What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation?[J]. Am J Transplant, 2020, 20(Suppl 4): 12-22. DOI: 10.1111/ajt.15859.
[4]	JAIN D, RAJAB A, YOUNG JS, et al. Reversing donorspecific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients[J]. Am J Transplant, 2020, 20(10): 2675-2685. DOI: 10.1111/ajt.15881.
[5]	JORDAN SC, AMMERMAN N, CHOI J, et al. The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(Suppl 4): 42-56. DOI: 10.1111/ajt.15913.
[6]	CHONG AS. Mechanisms of organ transplant injury mediated by B cells and antibodies: implications for antibody-mediated rejection[J]. Am J Transplant, 2020, 20(Suppl 4): 23-32. DOI: 10.1111/ajt.15844.
[7]	LOUIS K, MACEDO C, BAILLY E, et al. Coordinated circulating T follicular helper and activated B cell responses underlie the onset of antibody-mediated rejection in kidney transplantation[J]. J Am Soc Nephrol, 2020, 31(10): 2457-2474. DOI: 10.1681/ASN.2020030320.
[8]	SAKAMOTO S, IWASAKI K, TOMOSUGI T, et al. Analysis of T and B cell epitopes to predict the risk of de novo donor-specific antibody (DSA) production after kidney transplantation: a two-center retrospective cohort study[J]. Front Immunol, 2020, 11: 2000. DOI: 10.3389/fimmu.2020.02000.
[9]	SENEV A, LERUT E, VAN SANDT V, et al. Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation[J]. Am J Transplant, 2019, 19(11): 3100-3113. DOI: 10.1111/ajt.15414.
[10]	GE S, CHU M, CHOI J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibodydependent cell-mediated cytotoxicity (ADCC) in vitro[J]. Transplantation, 2020, 104(8): 1574-1579. DOI: 10.1097/TP.0000000000003023.
[11]	MARKS WH, MAMODE N, MONTGOMERY RA, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial[J]. Am J Transplant, 2019, 19(10): 2876-2888. DOI: 10.1111/ajt.15364.
[12]	GLOTZ D, RUSS G, ROSTAING L, et al. Safety and efficacy of eculizumab for the prevention of antibodymediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies[J]. Am J Transplant, 2019, 19(10): 2865-2875. DOI: 10.1111/ajt.15397.
[13]	TAN EK, BENTALL A, DEAN PG, et al. Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases[J]. Transplantation, 2019, 103(11): 2397-2404. DOI: 10.1097/TP.0000000000002639.
[14]	LAVACCA A, PRESTA R, GAI C, et al. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibodymediated rejection in kidney transplantation[J]. Clin Transplant, 2020, 34(8): e13908. DOI: 10.1111/ctr.13908.
[15]	SHIN BH, EVERLY MJ, ZHANG H, et al. Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection[J]. Transplantation, 2020, 104(4): 856-863. DOI: 10.1097/TP.0000000000002895.
[16]	KWUN J, KNECHTLE S. Experimental modeling of desensitization: what have we learned about preventing AMR?[J]. Am J Transplant, 2020, 20(Suppl 4): 2-11. DOI: 10.1111/ajt.15873.
[17]	DOBERER K, KLÄGER J, GUALDONI GA, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection[J]. Transplantation, 2021, 105(2): 451-457. DOI: 10.1097/TP.0000000000003247.
[18]	CUCCHIARI D, MOLINA-ANDUJAR A, MONTAGUDMARRAHI E, et al. Use of de novo mTOR inhibitors in hypersensitized kidney transplant recipients: experience from clinical practice[J]. Transplantation, 2020, 104(8): 1686-1694. DOI: 10.1097/TP.0000000000003021.
[19]	SCHINSTOCK CA, MANNON RB, BUDDE K, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from The Transplantion Society Working Group[J]. Transplantation, 2020, 104(5): 911-922. DOI: 10.1097/TP.0000000000003095.
[20]	OSSMAN R, JAMME M, MOULIN B, et al. Immunosuppression and graft rejection in living-related HLA-identical renal transplantation: the RADOVFULL study[J]. Transplantation, 2020, 104(6): 1256-1262. DOI: 10.1097/TP.0000000000002937.
[21]	SAWITZKI B, HARDEN PN, REINKE P, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials[J]. Lancet, 2020, 395(10237): 1627-1639. DOI: 10.1016/S0140-6736(20)30167-7.
[22]	ROEMHILD A, OTTO NM, MOLL G, et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial[J]. BMJ, 2020, 371: m3734. DOI: 10.1136/bmj.m3734.
[23]	LEE KW, PARK JB, PARK H, et al. Inducing transient mixed chimerism for allograft survival without maintenance immunosuppression with combined kidney and bone marrow transplantation: protocol optimization[J]. Transplantation, 2020, 104(7): 1472-1482. DOI: 10.1097/TP.0000000000003006.
[24]	PHAM C, KUTEN SA, KNIGHT RJ, et al. Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab[J]. Transpl Infect Dis, 2020, 22(3): e13257. DOI: 10.1111/tid.13257.
[25]	ELHELOU G, RAZONABLE R. Next-generation sequencing to assess cytomegalovirus viral populations during the course of CMV infection[J]. Am J Transplant, 2020, 20(Suppl 3): 793.
[26]	MALONEY E, TOH J, KRAMS SM, et al. Genomewide analysis of epstein barr virus identifies variations in the latency gene EBNA3C that are associated with post transplant lymphoproliferative disorder[J]. Am J Transplant, 2020, 20(Suppl 3): 295.
[27]	RODRIGUEZ-CUBILLO B, DE LA HIGUERA MAM, LUCENA R, et al. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?[J]. Am J Transplant, 2020, 20(11): 3173-3181. DOI: 10.1111/ajt.16141.
[28]	KRUEGER KM, ISON MG, GHOSSEIN C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation[J]. Am J Kidney Dis, 2020, 75(3): 417-425. DOI: 10.1053/j.ajkd.2019.06.014.
[29]	KRISHNAMOORTHY S, GHOBADI A, SANTOS RD, et al. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder[J]. Am J Transplant, 2021, 21(2): 809-814. DOI: 10.1111/ajt.16367.
[30]	STITES E, KUMAR D, OLAITAN O, et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury[J]. Am J Transplant, 2020, 20(9): 2491-2498. DOI: 10.1111/ajt.15822.
[31]	OELLERICH M, SHIPKOVA M, ASENDORF T, et al. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study[J]. Am J Transplant, 2019, 19(11): 3087-3099. DOI: 10.1111/ajt.15416.
[32]	WEHMEIER C, KARAHAN GE, KROP J, et al. Donorspecific B cell memory in alloimmunized kidney transplant recipients: first clinical application of a novel method[J]. Transplantation, 2020, 104(5): 1026-1032. DOI: 10.1097/TP.0000000000002909.
[33]	SENEV A, OTTEN HG, KAMBUROVA EG, et al. Antibodies against ARHGDIB and ARHGDIB gene expression associate with kidney allograft outcome[J]. Transplantation, 2020, 104(7): 1462-1471. DOI: 10.1097/TP.0000000000003005.
[34]	YANG JYC, SARWAL RD, SIGDEL TK, et al. A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection[J]. Sci Transl Med, 2020, 12(535): eaba2501. DOI: 10.1126/scitranslmed.aba2501.
[35]	DOBERER K, SCHIEMANN M, STRASSL R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-a prospective observational trial[J]. Am J Transplant, 2020, 20(8): 2081-2090. DOI: 10.1111/ajt.15810.
[36]	BUI K, KILAMBI V, MEHROTRA S. Functional status-based risk-benefit analyses of high-KDPI kidney transplant versus dialysis[J]. Transpl Int, 2019, 32(12): 1297-1312. DOI: 10.1111/tri.13483.
[37]	MOTTER JD, LIYANAGE L, JACKSON KR, et al. Consequences of turning down high KDPI kidney organ offers for kidney transplant candidates[J]. Am J Transplant, 2020, 20(Suppl 3): 426.
[38]	SONNENBERG EM, HSU JY, COHEN JB, et al. Acute kidney injury in deceased organ donors and kidney transplant outcomes: a national cohort study using a novel data source[J]. Ann Surg, 2020, DOI: 10.1097/SLA.0000000000004597[Epub ahead of print].
[39]	YU S, LONG JJ, YU Y, et al. Survival benefit of accepting kidneys from older donation after cardiac death donors[J]. Am J Transplant, 2020, DOI: 10.1111/ajt.16198[Epub ahead of print].
[40]	JOCHMANS I, BRAT A, DAVIES L, et al. Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial[J]. Lancet, 2020, 396(10263): 1653-1662. DOI: 10.1016/S0140-6736(20)32411-9.
[41]	THOMPSON ER, BATES L, IBRAHIM IK, et al. Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation[J]. Am J Transplant, 2020, DOI: 10.1111/ajt.16100[Epub ahead of print].
[42]	UFFING A, PÉREZ-SÁEZ MJ, MAZZALI M, et al. Recurrence of FSGS after kidney transplantation in adults[J]. Clin J Am Soc Nephrol, 2020, 15(2): 247-256. DOI: 10.2215/CJN.08970719.
[43]	BATAL I, VASILESCU ER, DADHANIA DM, et al. Association of HLA typing and alloimmunity with posttransplantation membranous nephropathy: a multicenter case series[J]. Am J Kidney Dis, 2020, 76(3): 374-383. DOI: 10.1053/j.ajkd.2020.01.009.
[44]	HIRAMITSU T, TOMOSUGI T, FUTAMURA K, et al. Calcineurin inhibitor withdrawal is the significant risk factor for de novo DSA production in living donor kidney transplantation[J]. Am J Transplant, 2020, 20(Suppl 3): 849. http://www.researchgate.net/publication/341973812_P1636THE_IMPACT_OF_CALCINEURIN_INHIBITOR_WITHDRAWAL_ON_DE_NOVO_DSA_PRODUCTION_IN_LIVING_DONOR_KIDNEY_TRANSPLANTATION
[45]	Foster K, Perkins H, Patel N, et al. The impact of purposeful reductions in immunosuppression on clinical outcomes in kidney transplantation[J]. Am J Transplant, 2020, 20(Suppl 3): 384.
[46]	GUTIÉRREZ VÍLCHEZ E, VÁZQUEZ T, LÓPEZ V, et al. Impact on graft histology of steroid withdrawal versus standard immunosuppression: randomized, parallel group, controlled clinical trial in low immunological risk kidney transplant patients[J]. Am J Transplant, 2020, 20(Suppl 3): 443.
[47]	VAN LOON E, BERNARDS J, VAN CRAENENBROECK AH, et al The causes of kidney allograft failure: more than alloimmunity.a viewpoint article[J].Transplantation, 2020, 104(2): e46-e56.DOI: 10.1097/TP.0000000000003012.
[48]	DENIC A, MORALES MC, PARK WD, et al.Using computer-assisted morphometrics of 5-year biopsies to identify biomarkers of late renal allograft loss[J].Am J Transplant, 2019, 19(10): 2846-2854.DOI: 10.1111/ajt.15380.
[49]	REEVE J, BÖHMIG GA, ESKANDARY F, et al.Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers[J].Am J Transplant, 2019, 19(10): 2719-2731.DOI: 10.1111/ajt.15351.
[50]	DANOBEITIA JS, ZENS TJ, CHLEBECK PJ, et al.Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation[J].Am J Transplant, 2020, 20(6): 1513-1526.DOI: 10.1111/ajt.15777.
[51]	GANPULE A, PATIL A, SINGH A, et al.Roboticassisted kidney transplant: a single center experience with median follow-up of 2.8 years[J].World J Urol, 2020, 38(10): 2651-2660.DOI: 10.1007/s00345-019-02934-0.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (912) PDF downloads(186)

Highlights of international frontier hot spots and new progress on renal transplantation in 2020

doi: 10.3969/j.issn.1674-7445.2021.02.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Highlights of international frontier hot spots and new progress on renal transplantation in 2020

doi: 10.3969/j.issn.1674-7445.2021.02.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content